Related Experiment Video
Updated: Jan 8, 2026
Introducing Point Mutations into Human Pluripotent Stem Cells Using Seamless Genome Editing
Published on: May 10, 2020
CRISPR: a precise genome editing strategy for the treatment of hepatocellular carcinoma
Subhrojyoti Mukherjee1, Manish Kumar1
1Department of Pharmaceutics, ISF College of Pharmacy, Moga, India.
Introduction:
The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing tool provides novel therapeutic alternatives by promoting the gene alteration in adaptive T cells or malignant cells to combat Hepatocellular Carcinoma (HCC). More successful cancer treatments are now possible due to the capacity of precisely locating and modifying particular genetic abnormalities that promote malignancy growth and metastasis.
Areas Covered:
In this review, we address ongoing clinical trials, the possible similarities between CRISPR-based cancer treatments and current therapeutic choices, and how CRISPR technology can improve treatment outcomes for HCC while using the latest safety measures. Additionally, this analysis sheds light on the existing obstacles and potential future possibilities of applying CRISPR technology to the management of HCC, with a final objective of enhancing patient results and completely changing the field of HCC therapies.
Expert Opinion:
The urgent need for innovative therapies is underscored by the poor prognosis associated with severe hepatocellular carcinoma, despite recent advancements in clinical therapies. Through a special emphasis on invivo cancer cell targeting along with the generation of chimeric antigen receptor (CAR) T cells, including T cell receptor (TCR) T cells, this review analyses the uses of CRISPR methods in the therapy of HCC.
Insights
CRISPR gene editing offers new ways to treat Hepatocellular Carcinoma (HCC) by altering T cells or cancer cells. This technology precisely targets genetic defects, improving cancer treatment outcomes and patient results.
Area of Science:
- Oncology
- Gene Editing
- Hepatocellular Carcinoma Research
Background:
- Hepatocellular Carcinoma (HCC) has a poor prognosis despite recent therapeutic advancements.
- Novel therapies are urgently needed to improve outcomes for HCC patients.
- CRISPR technology presents a promising avenue for genetic modification in cancer treatment.
Purpose of the Study:
- To review the application of CRISPR gene-editing technology in Hepatocellular Carcinoma (HCC) therapy.
- To analyze ongoing clinical trials and compare CRISPR-based treatments with current therapeutic options.
- To explore the potential of CRISPR in improving HCC treatment outcomes and patient results.
Main Methods:
- Review of ongoing clinical trials involving CRISPR for HCC.
- Analysis of CRISPR's role in targeting cancer cells in vivo.
- Examination of CRISPR-mediated generation of chimeric antigen receptor (CAR) T cells and T cell receptor (TCR) T cells for HCC therapy.
Main Results:
- CRISPR enables precise genetic alteration in adaptive T cells and malignant cells for HCC treatment.
- The technology facilitates targeting specific genetic abnormalities driving cancer growth and metastasis.
- CRISPR-based strategies, including CAR T cells and TCR T cells, show potential for enhancing HCC therapy.
Conclusions:
- CRISPR gene editing offers novel therapeutic alternatives for Hepatocellular Carcinoma.
- The technology has the potential to significantly improve HCC treatment outcomes by precisely targeting genetic defects.
- Addressing current obstacles and implementing safety measures are crucial for the future application of CRISPR in HCC management.
Related Concept Videos
01:28CRISPR/Cas9 Genome Editing
01:59CRISPR
02:31Homologous Recombination
02:53CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...